Kaposi sarcoma (KS) is the most common neoplasm of people living with HIV today. In Sub-
Saharan Africa, KS is among the most common cancers in men, overall. Not only HIV …

Much has been learned since the discovery of KSHV in 1994 about its epidemiology and
pathology but much of what has been learned has yet to be translated into clinical practice …

Efficient genetic modification of herpesviruses such as Kaposi's sarcoma-associated
herpesvirus (KSHV) has come to rely on bacterial artificial chromosome (BAC) technology …

Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8) is
the etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric …

Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma–
associated herpesvirus. Unmet needs include therapies that are oral, anthracycline sparing …

Background: The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-
Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy …

Objectives: To assess the incidence, predictors, and outcomes of Kaposi sarcoma-
associated paradoxical immune reconstitution inflammatory syndrome (KS-IRIS) in …

Despite recent advances in our understanding of pathogenic mechanisms involved, the true
nature of Kaposi sarcoma remains an enigma. Four clinical variants have been described for …

Twenty years after its discovery [1], Kaposi's sarcoma herpesvirus (KSHV) or human
herpesvirus-8 (HHV-8) continues to be an enigmatic oncovirus, while AIDS-associated …

Background Kaposi's sarcoma remains the most common cancer in Sub‐Saharan Africa and
the second most common cancer in HIV‐infected patients worldwide. Since the introduction …